• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

    344.18 +0.31 (+0.09%)
    Streaming Delayed Price Updated: 9:33 AM EDT, Oct 6, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BeOne Medicines Ltd. - American Depositary Shares

    < Previous 1 2 3 Next >
    Analyst Expectations For BeOne Medicines's Future
     
    Via Benzinga
    China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
    Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
    Via Investor's Business Daily
    Topics Government
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
    These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
    Via Benzinga
    A Glimpse of BeiGene's Earnings Potential
     
    Via Benzinga
    Earnings Scheduled For August 6, 2025
     
    Via Benzinga
    BeiGene's Earnings: A Preview
     
    Via Benzinga
    Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
     
    Via Benzinga
    Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
    BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress. 
    Via Benzinga
    Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga
    BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    From BeOne Medicines Ltd.
    Via Business Wire
    European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
    From BeOne Medicines Ltd.
    Via Business Wire
    BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
    From BeOne Medicines Ltd.
    Via Business Wire
    BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
    BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
    Via Benzinga
    BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
    From BeOne Medicines Ltd.
    Via Business Wire
    European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
    From BeOne Medicines Ltd.
    Via Business Wire
    Earnings Scheduled For August 8, 2025
     
    Via Benzinga
    BeOne Medicines (ONC) Q2 EPS Soars 924%
    Via The Motley Fool
    BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
    From BeOne Medicines Ltd.
    Via Business Wire
    BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
    From BeOne Medicines Ltd.
    Via Business Wire
    BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
    From BeOne Medicines Ltd.
    Via Business Wire
    Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings)
     
    Via Benzinga
    BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
    From BeOne Medicines Ltd.
    Via Business Wire
    European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
    From BeOne Medicines Ltd.
    Via Business Wire
    AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
    Via Benzinga
    What 8 Analyst Ratings Have To Say About BeOne Medicines
     
    Via Benzinga
    BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
    From BeOne Medicines Ltd.
    Via Business Wire
    BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
    From BeOne Medicines Ltd.
    Via Business Wire
    AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio?
    Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff. 
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.